Akesis Pharmaceuticals Discontinues Sole Clinical Development Program and Announces Intent to File for Chapter 7 Bankruptcy
1/22/2009 6:46:08 AM
More...
|
Akesis Pharmaceuticals Announces Pipeline Expansion Strategy
11/6/2008 11:16:20 AM
More...
|
Akesis Pharmaceuticals Appoints Carl LeBel as CEO and Jay Lichter as Executive Chairman
11/5/2008 6:45:13 AM
More...
|
Akesis Pharmaceuticals Enters into Bridge Financing Transaction
9/30/2008 8:51:37 AM
More...
|
Akesis Pharmaceuticals Expands Preclinical Safety Program for Lead Product
9/22/2008 9:50:54 AM
More...
|
Akesis Pharmaceuticals Names Christos Mantzoros, MD, DSc to its Scientific Advisory Board
7/18/2008 10:18:33 AM
More...
|
Akesis Pharmaceuticals Names Carl LeBel as President and Chief Operating Officer
6/30/2008 9:47:24 AM
More...
|
Akesis Pharmaceuticals and Charles River Laboratories (Massachusetts) to Begin 13-Week Animal Study for AKP- 020
6/24/2008 9:55:52 AM
More...
|
Akesis Pharmaceuticals Reports Positive Results from its Phase IIa Trial of AKP-020 for Type 2 Diabetes
6/17/2008 6:37:33 AM
More...
|
Akesis Pharmaceuticals Completes Phase IIa Trial of AKP-020 for Type 2 Diabetes
6/4/2008 9:53:04 AM
More...
|
|